AI-generated summary
This review outlines myopia's epidemiology, pathogenesis and intervention strategies, with particular attention to repeated low-level red light therapy, a photobiomodulation technique. The authors report promising efficacy of this therapy for controlling axial elongation and refractive error progression. They describe emerging mechanistic evidence involving mitochondrial cytochrome c oxidase, retinal metabolism, choroidal changes and scleral remodeling, and discuss feasibility from a safety perspective. The underlying biological mechanisms of myopia are described as still unclear.
- Who or what was studied
- unclear
- Limits stated in the abstract
- The abstract describes a narrative review and does not report a number of included studies, participants, or the strength of the evidence for the mechanisms discussed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Myopia is a major global public health concern, with a particularly high and increasing prevalence in East Asia. Although significant progress has been made in regard to developing strategies to slow the progression of myopia, the precise biological mechanisms underlying the onset and progression of myopia remain unclear. Repeated low-level red light (RLRL) therapy, a novel non-invasive photobiomodulation (PBM) technique, has demonstrated promising efficacy for controlling axial elongation and refractive error progression. This review first outlines the clinical definition, epidemiology, and global health impact of myopia, followed by the etiology-based pathogenesis and corresponding intervention strategies. Special attention has been given to emerging mechanistic evidence supporting RLRL, particularly its role in activating mitochondrial cytochrome c oxidase (CCO), enhancing retinal metabolism, influencing choroidal changes in blood perfusion and thickness, and in scleral remodeling. Finally, the feasibility and potential mechanism of the RLRL therapy for slowing myopia progression have been discussed from the perspective of safety.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Myopia, Repeated low-level red light, Cytochrome c oxidase, Photobiomodulation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.